Pancreatic adenocarcinoma Trials in New York, United States
Conditions / Pancreatic adenocarcinoma / New York, United States
Pancreatic adenocarcinoma is a medical condition with active clinical research programs worldwide.
30 total trials for this combination
Showing top 10 of 30 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | UNKNOWN | PHASE2 |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | TERMINATED | PHASE1 |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | COMPLETED | PHASE3 |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | RECRUITING | PHASE1 |
| NCT05877599 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | RECRUITING | — |
| NCT03678883 | 9-ING-41 in Patients with Advanced Cancers | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | RECRUITING | — |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | RECRUITING | PHASE1 |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | COMPLETED | PHASE1 |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | RECRUITING | PHASE1/PHASE2 |